[1] Lampropoulos P, Zizi-Sermpetzoglou A, Rizos S, et al. TGF-beta signalling in colon carcinogenesis [J]. Cancer Lett, 2012,314 (1):1-7.[2] Santibanez JF, Pérez-Gómez E, FernandezLA, et al. The TGF-beta co-receptor endoglin modulates the expression and transforming potential of H-Ras [J]. Carcinogenesis, 2010,31(12):2145-2154.[3] Edge S, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual[M].7th ed. New York, NY: Springer, 2010:347-376.[4] Tavassoli FA, Devilee P. WHO classification of tumours. Pathology & genetics tumors of the breast and female genital organs[M].Lyon: IARC Press, 2003:10.[5] Todorovic -Rakovic N, Milovanovic J, Nikolic-Vukosavljevic D . TGF-β and its coreceptors in cancerogenesis: an overview[J]. Biomark Med, 2011,5(6):855-863.[6] Massagué J. TGFβ signalling in context[J]. Nat Rev Mol Cell Biol, 2012,13(10):616-630.[7] Yang G, Yang X. Smad4-mediated TGF-beta signaling in tumorigenesis [J]. Int J Biol Sci, 2010,6(1):1-8.[8] Liu N, Yu C, Shi Y, et al.SMAD4 expression in breast ductal carcinoma correlates with prognosis[J].Oncol Lett, 2015,10(3):1709-1715.[9] Liu NN, Xi Y, Callaghan MU,et al. SMAD4 is a potential prognostic marker in human breast carcinomas[J].Tumour Biol, 2014,35(1):641-650.[10] Miller DV, Leontovich AA, Lingle WL, et al. Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas [J]. Mod Pathol, 2004, 17(7): 756-764.[11] Stuelten CH, Buck MB, Dippon J, et al. Smad4-expression is decreased in breast cancer tissues: a retrospective study [J]. BMC Cancer, 2006, 6(1):25-34.[12] Dumont E, Lallemand F, Prunier C, et al. Evidence for a role of Smad3 and Smad2 in stabilization of the tumor-derived mutant Smad2.Q407R [J]. J Biol Chem, 2003, 278 (27): 24881-24887.[13] Xu J, Attisano L. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway [J]. Proc Natl Acad Sci U S A, 2000, 97 (9): 4820-4825.[14] Hoot KE, Lighthall J, Han G, et al. Keratinocyte-specific Smad2 ablation results in increased epithelial-mesenchymal transition during skin cancer formation and progression [J]. J Clin Invest, 2008, 118 (8): 2722-2732.[15] Liang M, Liang YY, Wrighton K, et al. Ubiquitination and proteolysis of cancer-derived Smad4 mutants by SCFSkp2 [J]. Mol Cell Biol, 2004, 24 (17): 7524-7537.[16] Caldarella A, Crocetti E, Bianchi S, et al. Female breast cancer status according to ER, PR and HER2 expression: a population based analysis [J]. Pathol Oncol Res, 2011, 17(3):753-758.[17] Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer [J]. Biochim Biophys Acta, 1994,1198 (2/3): 165-184.[18] Kretzschmar M. Transforming growth factor-beta and breast cancer: Transforming growth factor-beta/SMAD signaling defects and cancer [J]. Breast Cancer Res, 2000,2(2):107-115. |